Skip to main content

Table 2 Association of quartiles of baseline markers of oxidative stress with baseline ESA resistance index (ERI) in maintenance hemodialysis patients

From: Association of plasma F2-isoprostanes and isofurans concentrations with erythropoiesis-stimulating agent resistance in maintenance hemodialysis patients

 

Concentration

Model 1a

Model 2b

Model 3c

β

95 % CI

P-valued

β

95 % CI

P-valued

β

95 % CI

P-valued

F2-Isoprostanes (ng/ml)

<0.049

Reference

-

-

Reference

-

-

Reference

-

-

0.049–< 0.063

−0.54

−6.06, 4.98

0.85

−3.02

−9.13, 3.09

0.33

−2.87

−9.09, 3.35

0.36

0.063–< 0.087

−2.03

−6.10, 2.04

0.33

−2.21

−7.95, 3.52

0.45

−2.40

−7.94, 3.14

0.39

≥0.087

5.04

−2.00, 12.1

0.16

8.00

−1.53, 17.5

0.10

6.44

−2.54, 15.4

0.16

Isofurans (ng/ml)

<0.25

Reference

-

-

Reference

-

-

Reference

-

-

0.25–< 0.45

6.67

1.55, 11.8

0.01

5.61

0.24, 10.98

0.04

5.29

0.003, 10.6

0.050

0.45–< 0.73

4.42

−0.31, 9.25

0.07

3.99

−1.74, 9.74

0.17

2.41

−3.52, 8.34

0.42

≥0.73

7.49

1.14, 13.8

0.02

9.45

1.49, 17.4

0.02

9.10

1.25, 16.9

0.02

  1. ERI defined as the weekly weight-adjusted ESA dose (units/kg/week) divided by the baseline hemoglobin level (g/dl)
  2. ESA Erythropoeisis stimulating agent, hsCRP High-sensitivity C-reactive protein
  3. a Unadjusted
  4. b Adjusted for age, sex, race, body mass index, etiology of end stage renal disease, diabetes status, transferrin saturation (serum iron/total iron binding capacity), Kt/V, and serum parathyroid hormone
  5. c Adjusted for Model 2 covariates plus hsCRP
  6. d P-values obtained from comparing regression coefficients to coefficient for lowest quartile of each inflammatory marker